Ryanodine Receptor 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ryanodine receptor 1 (RyR1) is a massive intracellular calcium release channel located primarily in the sarcoplasmic reticulum (SR) of skeletal muscle cells, where it plays a central role in excitation-contraction coupling. It is one of the largest known ion channels, forming a homotetrameric complex of approximately 2.2 MDa. RyR1 is activated by physical interaction with voltage-gated calcium channels (Cav1.1) in the T-tubule membrane during depolarization, bypassing the need for calcium-induced calcium release. In neurons, RyR1 is expressed in various brain regions including the hippocampus and cerebellum, where it contributes to synaptic plasticity, dendritic spine morphology, and calcium signaling in presynaptic terminals. Dysregulation of RyR1 is implicated in muscle disorders (malignant hyperthermia, central core disease) and neurodegenerative diseases including Alzheimer's and Parkinson's disease.
| Ryanodine Receptor 1 Protein | |
|---|---|
| Protein Name | Ryanodine Receptor 1 Protein |
| Gene | RYR1 |
| UniProt ID | P21810 |
| PDB IDs | 5TB1, 4W2D, 3J5H |
| Molecular Weight | 564 kDa |
| Subcellular Location | Sarcoplasmic reticulum membrane |
| Protein Family | Ryanodine receptor family |
Ryanodine Receptor 1 Protein is a Ryanodine receptor family. This protein contains characteristic transmembrane domains and regulatory domains that control channel activity and calcium release.
RYR1 is a large calcium release channel on the sarcoplasmic reticulum in skeletal muscle. It is the primary pathway for calcium release during excitation-contraction coupling, activated by voltage-gated calcium channel (Cav1.1) interaction rather than IP3. RYR1 is also expressed in neurons where it participates in synaptic calcium signaling. It forms homotetramers and is regulated by calcium, magnesium, and FKBP12.
RYR1 mutations cause central core disease (CCD) and malignant hyperthermia (MH). Altered RYR1 function is implicated in AD and muscle weakness in the elderly. RYR1 dysregulation affects synaptic plasticity.
Dantrolene is approved for malignant hyperthermia treatment. Novel RYR1 modulators are under development for CCD and muscle disorders.
The study of Ryanodine Receptor 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.